Skip to main content

Advertisement

Log in

Can signal peptide-CUB-EGF domain-containing protein (SCUBE) levels be a marker of angiogenesis in patients with psoriasis?

  • Original Paper
  • Published:
Archives of Dermatological Research Aims and scope Submit manuscript

Abstract

Angiogenesis is an important process being involved in the pathogenesis of psoriasis and promises new potential parameter for diagnosis and screening of treatment. This study investigated the levels of signal peptide-CUB-EGF (epidermal growth factor-like protein) family domain-containing protein (SCUBE) 1 and 3. Potential value as a novel marker of angiogenesis in patients with psoriasis is also evaluated by assessing possible relation of SCUBE-1 and 3 with disease activity in conjunction with vascular endothelial growth factor (VEGF) levels, as an established marker of angiogenesis. Forty-eight patients with psoriasis (aged >18 years) and 48 age- and gender-matched healthy controls were included. Detailed information was obtained through history and physical examination. Psoriasis area and severity index (PASI) scores were calculated. Blood SCUBE 1 and 3, and VEGF levels were measured by enzyme-linked immunosorbent assay. The mean PASI score of the patients was 6.7 ± 4.1. Patients’ serum SCUBE 1 and 3 and VEGF levels were significantly higher than those of the controls (P = 0.001). The sensitivity and specificity were calculated as 83 and 62% for the 0.67 ng/ml cut-off level of SCUBE 1, and 63 and 71% for the 2.57 ng/ml cut-off level of SCUBE 3, respectively. A cut-off VEGF level of 310 ng/mL predicted the presence of psoriasis with a sensitivity of 50% and specificity of 77%. The results of this pioneering study indicate that SCUBE protein family appears to have a probable role in the pathogenesis and angiogenesis development in psoriasis and SCUBE 1 and 3 may be novel markers of angiogenesis in psoriasis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Boehncke WH, Schon MP (2015) Psoriasis. Lancet 386(9997):983–994

    Article  CAS  PubMed  Google Scholar 

  2. Campanati A, Goteri G, Simonetti O, Ganzetti G, Giuliodori K, Giuliano A (2009) Angiogenesis in psoriatic skin and its modifications after administration of etanercept: videocapillaroscopic, histological and immunohistochemical evaluation. Int J Immunopathol Pharmacol 22:371–377

    Article  CAS  PubMed  Google Scholar 

  3. Chandra A, Ray A, Senapati S, Chatterjee R (2015) Genetic and epigenetic basis of psoriasis pathogenesis. Mol Immunol 64:313–323

    Article  CAS  PubMed  Google Scholar 

  4. Detmar M, Brown LF, Claffey KP, Yeo KT, Kocher O, Jackman RW, Berse B, Dvorak HF (1994) Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 180:1141–1146

    Article  CAS  PubMed  Google Scholar 

  5. Fernandez A (2015) Dermatology update: the dawn of targeted treatment. Cleve Clin J Med 82:309–320

    Article  PubMed  Google Scholar 

  6. Folkman J (1972) Angiogenesis in psoriasis: therapeutic implications. J Invest Dermatol 59:40–43

    Article  CAS  PubMed  Google Scholar 

  7. Goel S, Wong AH, Jain RK (2012) Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease. Cold Spring Harb Perspect Med 2: a006486.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Gudjonsson JE, Johnston A, Sigmundsdottir H, Valdimarsson H (2004) Immunopathogenic mechanisms in psoriasis. Clin Exp Immunol 135:1–8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Heidenreich R, Rocken M, Ghoreschi K (2009) Angiogenesis drives psoriasis pathogenesis. Int J Exp Pathol 90:232–248

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Lin YC, Chen CC, Cheng CJ, Yang RB (2011) Domain and functional analysis of a novel breast tumor suppressor protein, SCUBE2. J Biol Chem 286:39–47

    Google Scholar 

  11. Lin YC, Roffler SR, Yan YT, Yang RB (2015) Disruption of Scube2 impairs endochondral bone formation. J Bone Miner Res 30:1255–1267

    Article  CAS  PubMed  Google Scholar 

  12. Lin YC, Lee YC, Li LH, Cheng CJ, Yang RB (2014) Tumor suppressor SCUBE2 inhibits breast-cancer cell migration and invasion through the reversal of epithelial-mesenchymal transition. J Cell Sci 127:85–100

    Article  PubMed  Google Scholar 

  13. Li W, Man XY, Chen JQ, Zhou J, Cai SQ, Zheng M (2014) Targeting VEGF/VEGFR in the treatment of psoriasis. Discov Med 18:97–104

    PubMed  Google Scholar 

  14. Mezentsev A, Nikolaev A, Bruskin S (2014) Matrix metalloproteinases and their role in psoriasis. Gene 540:1–10

    Article  CAS  PubMed  Google Scholar 

  15. Mentese A, Fidan E, Sumer AU, Karahan SC, Sonmez M, Altay DU (2012) Is SCUBE 1 a new biomarker for gastric cancer? Cancer Biomark 11:191–195

    Article  CAS  PubMed  Google Scholar 

  16. Nofal A, Al-Makhzangy I, Attwa E, Nassar A, Abdalmoati A (2009) Vascular endothelial growth factor in psoriasis: an indicator of disease severity and control. J Eur Acad Dermatol Venereol 23:803–806

    Article  CAS  PubMed  Google Scholar 

  17. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM (2013) Identification and management of psoriasis and associated comorbidity project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 133:377–385

    Article  CAS  PubMed  Google Scholar 

  18. Schonthaler HB, Huggenberger R, Wculek SK, Detmar M, Wagner EF (2009) Systemic anti-VEGF treatment strongly reduces skin inflammation in a mouse model of psoriasis. Proc Natl Acad Sci USA 106:21264–21269

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Tu CF, Tsao KC, Lee SJ, Yang RB (2014) SCUBE3 (signal peptide-CUB-EGF domain-containing protein 3) modulates fibroblast growth factor signaling during fast muscle development. J Biol Chem 289:28–42

    Article  Google Scholar 

  20. Varricchi G, Granata F, Loffredo S, Genovese A, Marone G (2015) Angiogenesis and lymphangiogenesis in inflammatory skin disorders. J Am Acad Dermatol 73:144–153

    Article  CAS  PubMed  Google Scholar 

  21. Wu YY, Peck K, Chang YL et al (2011) SCUBE3 is an endogenous TGF-beta receptor ligand and regulates the epithelial mesenchymal transition in lung cancer. Oncogene 30:682–693

    Google Scholar 

  22. Yanga M, Mingyang G, Yonghe H Jiang Y (2013) Scube regulates synovial angiogenesis-related signaling. Med Hypotheses 81:948–953

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Arzu Aydın Capkin.

Ethics declarations

Conflicts of interest

None.

Ethical approval

The study protocol was approved by Kanuni Sultan Suleyman Research and Training Hospital Ethics Committee on Research.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Capkin, A.A., Demir, S., Mentese, A. et al. Can signal peptide-CUB-EGF domain-containing protein (SCUBE) levels be a marker of angiogenesis in patients with psoriasis?. Arch Dermatol Res 309, 203–207 (2017). https://doi.org/10.1007/s00403-017-1722-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00403-017-1722-7

Keywords

Navigation